TriLogic Pharma Receives Issue Notification from U.S. Patent Office For Drug Delivery Platform
Technology will be utilized in future drug development.
August 6, 2013

TriLogic Pharma announced today that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for its patent application covering TRI-726, its sustained release, self solidifying, bioeroding, drug delivery platform.

Jim Harwick, President of TriLogic Pharma, said, “We are excited that the USPTO has issued the patent for our proprietary drug delivery system. We continue to be pleased with the versatility of TRI-726 and the wide range of therapeutic classes and actives that can be developed with our novel delivery platform.”